Vaximm will start a clinical trial on the first ever investigational oral cancer vaccine, the company announced today.
The study will enrol 45 pancreatic cancer patients who will receive several doses of the VXM01 vaccine, which is designed to stimulate the immune system to destroy the blood vessels essential for tumour growth.
Go deeper with GlobalData
Patients will treated at the Heidelberg University Hospital in Germany and results of the study will be announced in the first half of 2013.
The vaccine is the first cancer vaccine being investigated, which is given orally and which acts in the gut to induce an anti-tumour response of the immune system.
Principal investigator Dr Hubertus Schmitz-Winnenthal said, "I am delighted about the transition of this therapeutic cancer vaccine into clinical evaluation. In animal experiments conducted by us and others, VXM01 showed an impressive anti-tumour activity.
See Also:
"We are very keen on exploring the safety and potential efficacy of this vaccine in inoperable pancreatic cancer patients, as a first step in the clinical evaluation of VXM01."
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataCaption: Oral vaccines are currently used to prevent diseases such as polio.
